Edesa Biotech licensed paridiprubart (EB05), its anti-TLR4 monoclonal antibody for acute respiratory distress syndrome, to Kyorin Pharmaceutical for Japan. Under the agreement dated November 8 and disclosed in an 8-K filed November 9, Kyorin pays 12 million dollars upfront, with development and regulatory milestones of up to 55 million dollars, sales milestones of up to 12.0 billion yen, and low double-digit tiered royalties. Kyorin funds development and commercialisation in Japan and holds a right of first negotiation for acute kidney injury; Edesa keeps all rights elsewhere and retains manufacturing. Edesa also terminated its at-the-market offering agreement with H.C. Wainwright, effective November 16, which removes a dilutive funding channel the day after signing a cash-bearing licence.
Five international liver societies, EASL, AASLD, APASL, ALEH and SOLDA, have published a unified global definition of acute-on-chronic liver failure, announced October 30 and presented at The Liver Meeting on November 7. The consensus defines liver failure as bilirubin of at least 5 mg/dL with an INR of at least 1.5, requires at least one extrahepatic organ dysfunction or failure alongside it, and grades severity by the count of organ failures across three grades. The 81-statement paper, published jointly in Hepatology and the Journal of Hepatology among others, includes trial endpoint recommendations informed by discussions with the FDA. Regional definitions had differed for years, which made cross-border trial populations hard to compare; a single standard is the precondition for registrational programmes in the syndrome.
Alerting nearby trained volunteers by smartphone app did not increase bystander CPR or AED use before professional responders arrived, in a randomised study across British Columbia and Columbus, Ohio, reported at the American Heart Association’s Resuscitation Science Symposium. Bystander CPR or AED use occurred in 69 percent of arrests with PulsePoint Respond alerts against 72 percent with standard dispatch alone, among 355 arrests in the primary analysis, with survival to hospital discharge of about 21 percent in each group. The findings are a conference abstract, preliminary and not peer reviewed, and they sit alongside today’s RACE-CARS result: two different ways of mobilising bystanders, both neutral on their primary measures.